Cohera Medical, a Pittsburgh, PA-based developer of absorbable surgical adhesives and sealants, secured an additional $9.3m to close its Series D financing, now at $26.3m.
The company will use the funds to drive toward U.S. regulatory approval for its TissuGlu® Surgical Adhesive, an internal surgical adhesive for large flap surgeries, and CE Marking approval for its Sylys® Surgical Sealant designed to reduce anastomotic leakage in gastrointestinal procedures.
Led by Patrick Daly, President and CEO, Cohera Medical received CE Marking approval for TissuGlu and began selling product to hospitals and surgeons in Germany in 2011. In the U.S., the company submitted the fourth and final module in a PMA application to the FDA.
Cohera’s second product, Sylys Surgical Sealant, is used in conjunction with standard anastomotic closure techniques to protect the suture or staple line, supporting the anastomosis during the first few days of healing, when leaks are most likely to occur.
19/12/2011: Cohera Medical Raises $25M in Series C Financing